ReviewFrontiers in microbiology2026
Progress on the correlation between sepsis and gut microbiota: a narrative review.
Review in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sepsis is a life-threatening organ dysfunction with high mortality. Gut microbiota plays a key role in sepsis pathogenesis, but evidence is often mixed. Methods: This narrative review is based on a structured literature search (PubMed, Web of Science, Cochrane; from database inception to March 15, 2025). Findings are stratified into clinical (human), preclinical (animal), and unsafe/unproven categories. Results: Sepsis and gut microbiota form a bidirectional vicious cycle. Sepsis induces dysbiosis via ischemia, inflammation, and broad-spectrum antibiotics - the strongest iatrogenic driver. Dysbiosis in turn amplifies organ dysfunction through gut-brain, gut-lung, gut-liver, gut-kidney, and gut-heart/spleen axes. Clinically, adequate source control and antibiotic de-escalation are mandatory before any microbiota-directed therapy. Microbiota-targeted interventions show promise but carry significant risks: live probiotics are contraindicated in septic shock, severe pancreatitis, and immunocompromised patients (PROPATRIA trial). Conclusion: This evidence-stratified review provides a clinical roadmap: prioritize source control and antibiotic stewardship; avoid live probiotics in high-risk sepsis. Future research requires large RCTs and personalized strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.